Covid19 Clinical Trial
— SAVE-MOREOfficial title:
suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial
Verified date | September 2022 |
Source | Hellenic Institute for the Study of Sepsis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by the ordinal scale of the 11-point World Health Organization (WHO) clinical progression scale (CPS).
Status | Completed |
Enrollment | 606 |
Est. completion date | February 6, 2022 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age equal to or above 18 years 2. Male or female gender 3. In case of women, unwillingness to remain pregnant during the study period. 4. Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation in the Member State where the trial is planned. 5. Confirmed infection by SARS-CoV-2 virus 6. Findings in chest-X-ray or in chest computed tomography compatible with lower respiratory tract infection 7. Need for hospitalization for COVID-19. The need for hospitalization is defined by the attending physician taking into consideration clinical presentation, requirement for supportive care, potential risk factors for severe disease, and conditions at home, including the presence of vulnerable persons in the household. 8. Plasma suPAR =6ng/ml Exclusion Criteria: - Age below 18 years - Denial for written informed consent - Any stage IV malignancy - Any do not resuscitate decision - ?ny pO2/FiO2 (partial oxygen pressure to fraction of inspired oxygen) ratio less than 150 mmHg irrespective if the patient is under mechanical ventilation (MV) / non-invasive ventilation (NIV) / extracorporeal membrane oxygenation (ECMO) or not - Patient under MV or NIV or ECMO - Any primary immunodeficiency - Less than 1,500 neutrophils/mm3 - Plasma suPAR less than 6 ng/ml - Known hypersensitivity to anakinra - Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days. - Any anti-cytokine biological treatment the last one month - Severe hepatic failure defined as Child-Pugh stage of 3 - End-stage renal failure necessitating hemofiltration or peritoneal hemodialysis - Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study - Participation in any other interventional trial |
Country | Name | City | State |
---|---|---|---|
Greece | 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis | Alexandroupolis | |
Greece | • 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS | Athens | |
Greece | • Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA | Athens | |
Greece | 10th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens | Athens | |
Greece | 1st Department of Internal Medicine, AMALIA FLEMING Prefecture General Hospital of Melissia | Athens | |
Greece | 1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S. | Athens | |
Greece | 1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO | Athens | |
Greece | 1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION | Athens | |
Greece | 1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO | Athens | |
Greece | 1st University Department of Internal Medicine, General Hospital of Athens LAIKO | Athens | |
Greece | 1st University Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens | Athens | |
Greece | 2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO | Athens | |
Greece | 2nd Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens | Athens | |
Greece | 2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens | Athens | |
Greece | 3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S. | Athens | |
Greece | 3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA | Athens | |
Greece | 4th Department of Internal Medicine, ATTIKON University General Hospital | Athens | |
Greece | 4th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens | Athens | |
Greece | 5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens | Athens | |
Greece | COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING | Athens | |
Greece | Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens | Athens | |
Greece | Department of COVID-19, Evangelismos General Hospital | Athens | |
Greece | Department of Internal Medicine, General Hospital of Athens Elpis | Athens | |
Greece | Department of Pulmonary Medicine, General Hospital of Kerkyra | Corfu | |
Greece | 1st Department of Internal Medicine, General University Hospital of Ioannina | Ioánnina | |
Greece | Department of Internal Medicine, University General Hospital of Larissa, | Larissa | |
Greece | Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA | Patra | |
Greece | 2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO | Piraeus | |
Greece | 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki | Thessaloníki | |
Greece | 1st Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki | Thessaloníki | |
Greece | 2nd Department of Propedeutic Medicine, Ippokrateion University General Hospital of Thessaloniki | Thessaloníki | |
Greece | 3rd University Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki | Thessaloníki | |
Italy | Dipartimento di Medicina Dipartimento di Malattie Infettive, ASST Spedali civili | Brescia | |
Italy | Unità Operativa Clinica Malattie Infettive, Ospedale Policlinico San Martino | Genova | |
Italy | Dipartimento di Medicina Interna, Istituto Clinico Humanitas | Milano | |
Italy | Medicina Interna, Reumatologia, Immunologia, IRCCS San Raffaele | Milano | |
Italy | Dipartimento di Malattie Infettive e Tropicali e Microbiologia, IRCCS Ospedale Sacro Cuore Don Calabria | Negrar | |
Italy | Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose, IRCCS Lazzaro Spallanzani | Roma | |
Italy | Dipartimento Scienze di laboratorio e infettivologiche, Policlinico Universitario Agostino Gemelli | Roma | |
Italy | Dipartimento di Malattie infettive e tropicali-Università dell'Insubria, ASST dei Sette Laghi | Varese |
Lead Sponsor | Collaborator |
---|---|
Hellenic Institute for the Study of Sepsis |
Greece, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cost of hospitalization | Comparison of the cost of hospitalization between the two arms of treatment | 90 days | |
Other | Comparison of the distribution of frequencies of each score of a 5-scale patient state | Comparison of the distribution of frequencies of each score of the 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment by Day 28. This will be expressed as the distribution of the frequencies of each score of the scale in each arm of treatment by Day 60. The scale ranges from 0 (best outcome outpatients) to 5 (worst outcome-death) | 60 days | |
Other | Comparison of the distribution of frequencies of each score of a 5-scale patient state | Comparison of the distribution of frequencies of each score of the 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment by Day 28. This will be expressed as the distribution of the frequencies of each score of the scale in each arm of treatment by Day 90. The scale ranges from ) (best outcome-outpatients) to 5 (worst outcome-death) | 90 days | |
Primary | Comparison of the distribution of frequencies of each score of a 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment | Comparison of the distribution of frequencies of each score of the 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment by Day 28. This will be expressed as the distribution of the frequencies of each score of the scale in each arm of treatment by Day 28. The scale ranges from 0 (best outcome-asymptomatic) to 11 (worst outcome-death). | 28 days | |
Secondary | Absolute change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) | Comparison of the absolute change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment. The scale ranges from 0 (best outcome-asymptomatic) to 11 (worst outcome-death). | 28 days | |
Secondary | Relative change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) | Comparison of the relative change (%) of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment. The scale ranges from 0 (best outcome-asymptomatic) to 11 (worst outcome-death). | 28 days | |
Secondary | Absolute change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) | Comparison of the absolute change of the measure of the 11-point of WHO Clinical Progression nordinal Scale (CPS) between the two arms of treatment. The scale ranges from 0 (best outcome-asymptomatic) to 11 (worst outcome-death). | 14 days | |
Secondary | Relative change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) | Comparison of the relative (%) change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment. The scale ranges from 0 (best outcome-asymptomatic) to 11 (worst outcome-death). | 14 days | |
Secondary | Absolute change of the SOFA score | Comparison of the absolute change of the SOFA score (in points) between the two arms of treatment | 14 days | |
Secondary | Relative change of the SOFA score | Comparison of the relative (%) change of the SOFA score (in points) between the two arms of treatment | 14 days | |
Secondary | Absolute change of the SOFA score | Comparison of the absolute change of the SOFA score between the two arms of treatment | 7 days | |
Secondary | Relative change of the SOFA score | Comparison of the relative (%) change of the SOFA score between the two arms of treatment | 7 days | |
Secondary | Time until hospital discharge | Comparison of the time until hospital discharge between the two arms of treatment | 90 days | |
Secondary | Time until discharge from the intensive care unit | Comparison of the time until discharge from the intensive care unit between the two arms of treatment | 90 days | |
Secondary | Comparison of the rate of serious and non-serious adverse events between the two arms of treatment | Comparison of the rate of serious and non-serious adverse events between the two arms of treatment | 90 days | |
Secondary | Comparison of the rate of serious and non-serious adverse events between the two arms of treatment | Comparison of the rate of serious and non-serious adverse events between the two arms of treatment | 60 days | |
Secondary | Relative changes of circulating concentrations of suPAR (µg/liter), D-dimers (µg/liter), ferritin (µg/liter), and Interleukin-6 (µg/liter) by Day 7 from baseline Day 1 | Comparison of the relative changes of circulating concentrations of suPAR (µg/liter),D-dimers (µg/liter), ferritin (µg/liter), and Interleukin-6 (µg/liter) between the two arms of treatment | 7 days | |
Secondary | Relative changes of circulating concentrations of C-reactive protein (mg/liter) by Day 7 from baseline Day 1 | Comparison of the relative changes of circulating concentrations of C-reactive protein (mg/liter) between the two arms of treatment | 7 days | |
Secondary | Relative changes of circulating concentrations of suPAR (µg/liter),D-dimers (µg/liter), ferritin (µg/liter), and Interleukin-6 (µg/liter) by Day 4 from baseline Day 1 | Comparison of the relative changes of circulating concentrations of suPAR (µg/liter),D-dimers (µg/liter), ferritin (µg/liter), and Interleukin-6 (µg/liter) between the two arms of treatment | 4 days | |
Secondary | Relative changes of circulating concentrations of C-reactive protein (mg/liter) by Day 4 from baseline Day 1 | Comparison of the relative changes of circulating concentrations of C-reactive protein (mg/liter) between the two arms of treatment | 4 days | |
Secondary | Absolute change of the viral load by Day 7 from baseline Day 1 | Comparison of the absolute change of the viral load (in copies) between the two arms of treatment | 7 days | |
Secondary | Relative change of the viral load by Day 7 from baseline Day 1 | Comparison of the relative (%) change of the viral load between the two arms of treatment | 7 days | |
Secondary | Absolute change of the viral load by Day 4 from baseline Day 1 | Comparison of the absolute change of the viral load (in copies) between the two arms of treatment | 4 days | |
Secondary | relative change of the viral load by Day 4 from baseline Day 1 | Comparison of the relative change (%) of the viral load between the two arms of treatment | 4 days | |
Secondary | Transcriptomic analysis | Expression of messenger Ribonucleic Acid (mRNA) will be compared between the two arms of treatment | 7 days | |
Secondary | Proteomic analysis | Protein composition will be compared between the two arms of treatment | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |